title: 1D09C3, an mAb specific for MHC-II.
abstract: GPC Biotech AG is developing 1D09C3, an anti-MHC class II (HLA-DR) fully human IgG4 antibody isolated by MorphoSys AG (from its HuCAL library of human antibodies), for the potential treatment of hematological malignancies. In December 2006, positive safety data from two phase I clinical trials were reported. Final phase I data were expected in mid-2007; however, no additional data have been released at the time of publication.
authors.affiliation: Women's and Children's Health Research Institute, 72 King William Road, North Adelaide, SA 5006, South Australia. heddy.zola@adelaide.edu.au
authors.forename: Heddy
authors.initials: H
authors.lastname: Zola
authors.forename: Alice
authors.initials: A
authors.lastname: Beare
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology* / Q000493:pharmacokinetics; D061067:Antibodies, Monoclonal, Humanized; D000918:Antibody Specificity / Q000276:immunology*; D002986:Clinical Trials as Topic; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D010330:Patents as Topic; D013329:Structure-Activity Relationship
chemical_list: C528511:1D09C3 monoclonal antibody; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000949:Histocompatibility Antigens Class II